HomeCompareXVIPY vs ARCC

XVIPY vs ARCC: Dividend Comparison 2026

XVIPY yields 30.58% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XVIPY wins by $112.4K in total portfolio value
10 years
XVIPY
XVIPY
● Live price
30.58%
Share price
$6.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$136.9K
Annual income
$18,414.99
Full XVIPY calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — XVIPY vs ARCC

📍 XVIPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXVIPYARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XVIPY + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XVIPY pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XVIPY
Annual income on $10K today (after 15% tax)
$2,599.39/yr
After 10yr DRIP, annual income (after tax)
$15,652.74/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, XVIPY beats the other by $15,651.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XVIPY + ARCC for your $10,000?

XVIPY: 50%ARCC: 50%
100% ARCC50/50100% XVIPY
Portfolio after 10yr
$80.7K
Annual income
$9,208.07/yr
Blended yield
11.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

XVIPY
No analyst data
Altman Z
4.9
Piotroski
6/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XVIPY buys
0
ARCC buys
0
No recent congressional trades found for XVIPY or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXVIPYARCC
Forward yield30.58%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$136.9K$24.5K
Annual income after 10y$18,414.99$1.14
Total dividends collected$94.1K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: XVIPY vs ARCC ($10,000, DRIP)

YearXVIPY PortfolioXVIPY Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$13,758$3,058.10$11,373$532.74+$2.4KXVIPY
2$18,653$3,932.12$12,608$279.46+$6.0KXVIPY
3$24,941$4,982.42$13,809$142.90+$11.1KXVIPY
4$32,914$6,226.19$15,042$72.20+$17.9KXVIPY
5$42,896$7,678.77$16,341$36.27+$26.6KXVIPY
6$55,252$9,353.04$17,732$18.18+$37.5KXVIPY
7$70,379$11,258.95$19,231$9.10+$51.1KXVIPY
8$88,708$13,403.14$20,851$4.55+$67.9KXVIPY
9$110,707$15,788.69$22,605$2.28+$88.1KXVIPY
10$136,871$18,414.99$24,504$1.14+$112.4KXVIPY

XVIPY vs ARCC: Complete Analysis 2026

XVIPYStock

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Full XVIPY Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this XVIPY vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XVIPY vs SCHDXVIPY vs JEPIXVIPY vs OXVIPY vs KOXVIPY vs MAINXVIPY vs HTGCXVIPY vs GBDCXVIPY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.